Price T Rowe Associates Inc Tarsus Pharmaceuticals, Inc. Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
A detailed history of Price T Rowe Associates Inc transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 347,683 shares of TARS stock, worth $9.45 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
347,683Holding current value
$9.45 Million% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding TARS
# of Institutions
166Shares Held
39.5MCall Options Held
190KPut Options Held
92.9K-
Rtw Investments, LP New York, NY3.27MShares$88.9 Million1.91% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.86MShares$77.8 Million3.9% of portfolio
-
Black Rock Inc. New York, NY2.65MShares$72.1 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.4MShares$65.2 Million0.01% of portfolio
-
Tang Capital Management LLC San Diego, CA2.25MShares$61.3 Million9.98% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $725M
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...